Phase II study of dasatinib in patients with advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 28, Issue 30, 2010, Pages 4609-4615

  Johnson, Faye M ^a   Bekele, B Nebiyou ^a   Feng, Lei ^a   Wistuba, Ignacio ^a   Tang, Xi Ming ^a   Tran, Hai T ^a   Erasmus, Jeremy J ^a   Hwang, Li Ling ^a   Takebe, Naoko ^a   Blumenschein, George R ^a   Lippman, Scott M ^a   Stewart, David J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PROTEIN TYROSINE KINASE; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; RAS PROTEIN; THIAZOLE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEDTIME DOSAGE; CANCER CONTROL; CANCER TISSUE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FATIGUE; FEMALE; GENE MUTATION; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; HUMAN TISSUE; HYPOXIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MORNING DOSAGE; NAUSEA; NEUROPATHY; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; SIDE EFFECT; THORAX PAIN; THROMBOCYTOPENIA; TUMOR VOLUME; VOMITING; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PHOSPHORYLATION; TIME; TREATMENT OUTCOME; UNITED STATES;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CYTOKINES; DISEASE-FREE SURVIVAL; ENZYME ACTIVATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PHOSPHORYLATION; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PYRIMIDINES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SRC-FAMILY KINASES; TEXAS; THIAZOLES; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 78049495513     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.5474     Document Type: Article

References (40)

1. Johnson FM, Gallick G: Src Family Kinase Inhibitors in Cancer Therapy. Hauppauge, NY, Nova Science Publishers, 2009
2. Kim LC, Song L, Haura EB: Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 6:587-595, 2009
3. Masaki T, Igarashi K, Tokuda M, et al: pp60c-src activation in lung adenocarcinoma. Eur J Cancer 39:1447-1455, 2003
4. Zhang J, Kalyankrishna S, Wislez M, et al: SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol 170:366-376, 2007 (Pubitemid 47339214)
5. Johnson FM, Saigal B, Talpaz M, et al: Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11:6924-6932, 2005 (Pubitemid 41428750)
6. Purnell PR, Mack PC, Tepper CG, et al: The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells. J Thorac Oncol 4:448-454, 2009
7. Song L, Morris M, Bagui T, et al: Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res 66:5542-5548, 2006 (Pubitemid 43927102)
8. Fu YN, Yeh CL, Cheng HH, et al: EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: Implications in targeting therapy. Oncogene 27:957-965, 2008 (Pubitemid 351225379)
9. Chung BM, Dimri M, George M, et al: The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancerassociated EGF receptor mutants. Oncogene 28: 1821-1832, 2009
10. Leung EL, Tam IY, Tin VP, et al: SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy. Mol Cancer Res 7:923-932, 2009
11. Cabioglu N, Summy J, Miller C, et al: CXCL- 12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res 65:6493-6497, 2005 (Pubitemid 41060680)
12. Pal S, Datta K, Mukhopadhyay D: Central role of p53 on regulation of vascular permeability factor/ vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res 61:6952-6957, 2001 (Pubitemid 32896524)
13. Sounni NE, Roghi C, Chabottaux V, et al: Upregulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. J Biol Chem 279:13564-13574, 2004 (Pubitemid 38468882)
14. Sato M, Tanaka T, Maeno T, et al: Inducible expression of endothelial PAS domain protein-1 by hypoxia in human lung adenocarcinoma A549 cells: Role of Src family kinases-dependent pathway. Am J Respir Cell Mol Biol 26:127-134, 2002 (Pubitemid 34029829)
15. Johnson FM, Agrawal S, Burris H, et al: Phase I pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 116:1582-1591, 2009
16. Quintás-Cardama A, Kantarjian H, O'brien S, et al: Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25:3908-3914, 2007 (Pubitemid 47477268)
17. Miller AA, Pang H, Hodgson L, et al: A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602). J Thorac Oncol 5:380-384, 2010
18. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
19. Wahl RL, Jacene H, Kasamon Y, et al: From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 50:122S-150S, 2009 (suppl 1)
20. Demetri GD, Lo Russo P, MacPherson IR, et al: Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res 15:6232-6240, 2009
21. Haura EB, Tanvetyanon T, Chiappori A, et al: Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol 28:1387-1394, 2010
22. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002 (Pubitemid 34438899)
23. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006 (Pubitemid 44917502)
24. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
25. Sen B, Saigal B, Parikh N, et al: Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Cancer Res 69:1958-1965, 2009
26. Li J, Rix U, Fang B, et al: A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 6:291-299, 2010
27. Sos ML, Michel K, Zander T, et al: Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest 119:1727-1740, 2009
28. McDermott U, Ames RY, Iafrate AJ, et al: Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res 69:3937-3946, 2009
29. Braiteh F, Kurzrock R: Uncommon tumors and exceptional therapies: Paradox or paradigm? Mol Cancer Ther 6:1175-1179, 2007
30. Curtin JA, Busam K, Pinkel D, et al: Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24:4340-4346, 2006 (Pubitemid 46630793)
31. Yaren A, Oztop I, Kargi A, et al: Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis. Int J Clin Pract 60:675-682, 2006 (Pubitemid 43811647)
32. Pietsch T, Nicotra MR, Fraioli R, et al: Expression of the c-Kit receptor and its ligand SCF in non-small-cell lung carcinomas. Int J Cancer 75:171-175, 1998 (Pubitemid 28100054)
33. Schmid K, Oehl N, Wrba F, et al: EGFR/KRAS/ BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 15:4554-4560, 2009
34. Spruessel A, Steimann G, Jung M, et al: Tissue ischemia time affects gene and protein expression patterns within minutes following surgical tumor excision. Biotechniques 36:1030-1037, 2004 (Pubitemid 38747367)
35. Blackhall FH, Pintilie M, Wigle DA, et al: Stability and heterogeneity of expression profiles in lung cancer specimens harvested following surgical resection. Neoplasia 6:761-767, 2004 (Pubitemid 40041494)
36. Mager SR, Oomen MH, Morente MM, et al: Standard operating procedure for the collection of fresh frozen tissue samples. Eur J Cancer 43:828-834, 2007 (Pubitemid 46389483)
37. Kopetz S, Lesslie DP, Dallas NA, et al: Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 69:3842-3849, 2009
38. Ceppi P, Papotti M, Monica V, et al: Effects of Src kinase inhibition induced by dasatinib in non-mall cell lung cancer cell lines treated with cisplatin. Mol Cancer Ther 8:3066-3074, 2009
39. Raju U, Johnson FM, Glisson BS, et al: Mechanisms of enhanced radiosensitivity of human head and neck squamous cell carcinomas by dasatinib (BMS-354825, an inhibitor of Src kinases) include induction of apoptosis and inhibition of DNA repair, Proceedings of the American Association for Cancer Research, San Diego, CA, 2008, pp 642
40. Wheeler DL, Iida M, Kruser TJ, et al: Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther 8:696-703, 2009